| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10910823 | Lung Cancer | 2015 | 6 Pages |
Abstract
This baseline plasma biomarker signature is associated with improved outcome in advanced NSCLC patients receiving linifanib. Utility of the biomarker signature in patient selection for linifanib therapy in NSCLC merits evaluation in larger, prospective trials that are powered to detect a survival benefit.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Evelyn M. McKeegan, Peter J. Ansell, Gerard Davis, Sabrina Chan, Raj K. Chandran, Susan H. Gawel, Barry L. Dowell, Anahita Bhathena, Arunava Chakravartty, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, Suresh S. Ramalingam, Viswanath Devanarayan,